Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 9;25(6):3173.
doi: 10.3390/ijms25063173.

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer

Morgan Bailey  1 , Susan Morand  1 , Rachel Royfman  1 , Leslie Lin  1 , Aditi Singh  1 , Laura Stanbery  2 , Adam Walter  2   3 , Danae Hamouda  1 , John Nemunaitis  2
Affiliations
Review

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer

Morgan Bailey et al. Int J Mol Sci. .

Abstract

The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi's), has created additional opportunities for patients seeking frontline and recurrent disease management options. In particular, PARPi's have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer. Until recently, response was thought to be limited in BRCA wild-type, homologous recombination proficient (HRP) cancers. Therefore, attempts have been made at combination therapy involving PARPi to improve patient outcomes. Additionally, immune checkpoint inhibitors (ICIs) have demonstrated underwhelming results involving ovarian cancer. Many are searching for reliable biomarkers of immune response to increase efficacy of ICI therapy involving ovarian cancer. In this review, we examine the evidence supporting the combination of PARPi and ICIs in ovarian cancer, which is still lacking.

Keywords: BRCA; HRD; HRP; PARP inhibitor; checkpoint inhibitor; homologous recombination; immunotherapy; ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

John Nemunaitis was employed by, owns stock in, and is a board member of the company Gradalis, Inc. Laura Stanbery and Adam Walter are employees of Gradalis, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Staats H., Cassidy C., Kelso J., Mack S., Morand S., Choucair K., Qaqish H., Willis O., Craig D., Duff J., et al. Targeted Molecular Therapy in Palliative Cancer Management. Insights Biomed. 2020;5:3. doi: 10.36648/2572-5610.4.4.68. - DOI
    1. Bitler B.G., Watson Z.L., Wheeler L.J., Behbakht K. PARP inhibitors: Clinical utility and possibilities of overcoming resistance. Gynecol. Oncol. 2017;147:695–704. doi: 10.1016/j.ygyno.2017.10.003. - DOI - PMC - PubMed
    1. Franzese E., Centonze S., Diana A., Carlino F., Guerrera L.P., Di Napoli M., De Vita F., Pignata S., Ciardiello F., Orditura M. PARP inhibitors in ovarian cancer. Cancer Treat. Rev. 2019;73:1–9. doi: 10.1016/j.ctrv.2018.12.002. - DOI - PubMed
    1. Lightfoot M., Montemorano L., Bixel K. PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development? Curr. Oncol. Rep. 2020;22:29. doi: 10.1007/s11912-020-0873-4. - DOI - PubMed
    1. Ledermann J.A. PARP inhibitors in ovarian cancer. Ann. Oncol. 2016;27((Suppl. S1)):i40–i44. doi: 10.1093/annonc/mdw094. - DOI - PubMed

MeSH terms

Substances